De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Rain Oncology Toekomstige groei

Future criteriumcontroles 0/6

Rain Oncology zal naar verwachting dalen met 23.3% per jaar. De winst per aandeel zal naar verwachting groeien met 26.9% per jaar.

Belangrijke informatie

23.3%

Groei van de winst

26.9%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.7%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	03 Jan 2024

Recente toekomstige groei-updates

Recent updates

Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?

Feb 23

We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully

Nov 08

Winst- en omzetgroeiprognoses

NasdaqGS:RAIN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-30	N/A	N/A	1
12/31/2025	N/A	-26	N/A	N/A	1
12/31/2024	N/A	-46	N/A	N/A	2
12/31/2023	N/A	-64	N/A	N/A	2
9/30/2023	N/A	-72	-68	-66	N/A
6/30/2023	N/A	-83	-74	-74	N/A
3/31/2023	N/A	-79	-68	-68	N/A
12/31/2022	N/A	-76	-63	-63	N/A
9/30/2022	N/A	-71	-60	-60	N/A
6/30/2022	N/A	-71	-59	-56	N/A
3/31/2022	N/A	-62	-52	-50	N/A
12/31/2021	N/A	-51	-40	-37	N/A
9/30/2021	N/A	-39	-35	-32	N/A
6/30/2021	N/A	-31	-28	-23	N/A
3/31/2021	N/A	-25	-19	-14	N/A
12/31/2020	N/A	-21	-16	-11	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat RAIN de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat RAIN de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat RAIN de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van RAIN naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er wordt verwacht dat RAIN volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van RAIN naar verwachting over 3 jaar hoog zal zijn

Rain Oncology Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 69% to US$1.44

Price target decreased by 30% to US$4.65

Price target decreased by 59% to US$7.46

Price target increased by 7.4% to US$19.44

Price target decreased to US$18.00

Price target decreased to US$16.17

Recent updates

Rain Oncology Files Form 15

Rain Oncology to Delist from Nasdaq

Pathos AI, Inc. entered into a definitive merger agreement to acquire Rain Oncology Inc. (NasdaqGS:RAIN) for $42.2 million.

Pathos AI, Inc. entered into a definitive merger agreement to acquire Rain Oncology Inc. (NasdaqGS:RAIN) for $42.2 million.

New minor risk - Shareholder dilution

Price target decreased by 69% to US$1.44

Price target decreased by 30% to US$4.65

Rain Oncology Inc., Proterra Inc., Bioxcel Therapeutics, Inc Announces Class Action Update

Rain Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Levi & Korsinsky, LLP Files a Complaint to Recover Losses Suffered by Purchasers of Rain Oncology Inc. Securities

Price target decreased by 59% to US$7.46

Rain Oncology Inc. Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for Treatment of Dedifferentiated Liposarcoma

Price target increased by 7.4% to US$19.44

Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?

Rain Oncology Inc. Announces Phase 1 Clinical Data of Milademetan Publishes in Journal of Clinical Oncology

Senior VP & Head of Research notifies of intention to sell stock

lead Independent Director recently bought US$988k worth of stock

We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully

Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for Mdm2-Amplified Advanced Solid Tumors

Rain Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Price target decreased to US$18.00

Rain Therapeutics Inc. Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

Rain Therapeutics GAAP EPS of -$0.66 in-line

Here's Why We're Watching Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Situation

Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russell 2500 Value Index

Co-Founder recently bought US$57k worth of stock

Price target decreased to US$16.17

Price target decreased to US$18.00

Rain Therapeutics Inc., Annual General Meeting, Jun 01, 2022

We're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate

Co-Founder notifies of intention to sell stock

Rain Therapeutics Inc. Announces the Appointments of Several Industry Veterans to the Leadership Team

We Think Rain Therapeutics (NASDAQ:RAIN) Can Afford To Drive Business Growth

Independent Director recently bought US$54k worth of stock

We're Hopeful That Rain Therapeutics (NASDAQ:RAIN) Will Use Its Cash Wisely

Rain Therapeutics Inc. Presents Non-Clinical Data on Milademetan (RAIN-32) in Malignant Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer

Independent Director recently bought US$2.1m worth of stock

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven